Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Passes Below 200-Day Moving Average – Should You Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.38 and traded as low as $0.3572. Elite Pharmaceuticals shares last traded at $0.3716, with a volume of 253,657 shares.

Elite Pharmaceuticals Stock Down 1.1%

The firm has a market capitalization of $388.74 million, a price-to-earnings ratio of 18.05 and a beta of 0.40. The company has a current ratio of 6.45, a quick ratio of 5.22 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average price of $0.37 and a 200 day moving average price of $0.38.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.